YD Bio Ltd risk profile
64 Stretched several inputs deteriorating together
Measured 1 September 2026 from YDES's filed statements. Recomputed nightly.
64 (Stretched), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 83 | Acute | Volatile | One-year price volatility — 194.5% |
| Operating pressure | 69 | Stretched | Stable | Costs outgrowing revenue — +180.4 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.22x |
| Leverage and coverage | 0 | Contained | Easing | Net debt to EBITDA |
| Competitive position | 69 | Stretched | Stable | Operating-margin gap against peers — -858.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.